143 related articles for article (PubMed ID: 16785865)
1. Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano FA; Fehse B; Hotz-Wagenblatt A; Jonnakuty S; del Val C; Appelt JU; Nagy KZ; Kuehlcke K; Naundorf S; Zander AR; Zeller WJ; Ho AD; Fruehauf S; Laufs S
Bone Marrow Transplant; 2006 Aug; 38(3):229-35. PubMed ID: 16785865
[TBL] [Abstract][Full Text] [Related]
2. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function.
Robinet E; Fehse B; Ebeling S; Sauce D; Ferrand C; Tiberghien P
Cytotherapy; 2005; 7(2):150-7. PubMed ID: 16040394
[TBL] [Abstract][Full Text] [Related]
3. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
[TBL] [Abstract][Full Text] [Related]
4. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
Weijtens M; van Spronsen A; Hagenbeek A; de Weger R; Martens A
Exp Hematol; 2004 Oct; 32(10):962-9. PubMed ID: 15504552
[TBL] [Abstract][Full Text] [Related]
6. Gene transfer for activation of CMV specific T cells.
André-Schmutz I; Dal Cortivo L; Hamel Y; Cavazzana-Calvo M
Hum Immunol; 2004 May; 65(5):565-70. PubMed ID: 15172458
[TBL] [Abstract][Full Text] [Related]
7. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
8. Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line.
Tsukahara T; Agawa H; Matsumoto S; Matsuda M; Ueno S; Yamashita Y; Yamada K; Tanaka N; Kojima K; Takeshita T
Biochem Biophys Res Commun; 2006 Jul; 345(3):1099-107. PubMed ID: 16713998
[TBL] [Abstract][Full Text] [Related]
9. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.
Rappa G; Anzanello F; Alexeyev M; Fodstad O; Lorico A
Eur J Haematol; 2007 May; 78(5):440-8. PubMed ID: 17331133
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes.
Junker K; Koehl U; Zimmerman S; Stein S; Schwabe D; Klingebiel T; Grez M
Gene Ther; 2003 Jul; 10(14):1189-97. PubMed ID: 12833128
[TBL] [Abstract][Full Text] [Related]
11. Suicide gene therapy and the control of graft-vs-host disease.
Introna M; Rambaldi A
Best Pract Res Clin Haematol; 2004 Sep; 17(3):453-63. PubMed ID: 15498716
[TBL] [Abstract][Full Text] [Related]
12. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.
van Meerten T; Claessen MJ; Hagenbeek A; Ebeling SB
Gene Ther; 2006 May; 13(9):789-97. PubMed ID: 16421601
[TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.
Griffioen M; van Egmond HM; Barnby-Porritt H; van der Hoorn MA; Hagedoorn RS; Kester MG; Schwabe N; Willemze R; Falkenburg JH; Heemskerk MH
Haematologica; 2008 Oct; 93(10):1535-43. PubMed ID: 18768532
[TBL] [Abstract][Full Text] [Related]
14. T-cell therapy after hematopoietic stem cell transplantation.
Kennedy-Nasser AA; Brenner MK
Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
[TBL] [Abstract][Full Text] [Related]
15. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
16. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
17. [Possibility of selective induction of a GVL effect without increasing GVHD].
Akatsuka Y
Rinsho Ketsueki; 2008 Aug; 49(8):607-15. PubMed ID: 18800609
[No Abstract] [Full Text] [Related]
18. Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells.
Siapati EK; Bigger BW; Kashofer K; Themis M; Thrasher AJ; Bonnet D
Eur J Haematol; 2007 Apr; 78(4):303-13. PubMed ID: 17378892
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Transcription start regions in the human genome are favored targets for MLV integration.
Wu X; Li Y; Crise B; Burgess SM
Science; 2003 Jun; 300(5626):1749-51. PubMed ID: 12805549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
